Patent ID: 9745581
Date: 2017-08-29
CPC Classifications: A61K,C12N,C12Q,G01N

Claim:
1. A method of treating a cancer associated with a decrease in expression of MAP Kinase Interacting Serine/Threonine Kinase 2a (Mnk2a) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide agent that hybridizes to to a MAP Kinase Interacting Serine/Threonine Kinase (Mnk2 gene) transciption product such that the ratio of the splice variant MAP Kinase Interacting Serine/Threonine Kinase 2a (Mnk2a): MAP Kinase Interacting Serine/Threonine Kinase 2b (Mnk2b) is increased, thereby treating the cancer associated with a decrease in expression of Mnk2a.